ASH 2022 | The impact of IKZF1 alterations on clinical outcomes of patients in the Total Therapy XV/XVI studies
Ruth Wang'ondu
• 11 Dec 2022
Ruth Wang’ondu, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN, shares some findings from a retrospective study which analyzed the impact of various alterations in the IKZF1 gene on the clinical outcomes of patients enrolled in the St. Jude Total Therapy XV and XVI trials (NCT00137111; NCT00549848). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
